Research Topics
| A BesarabSummaryCountry: USA Publications
| Collaborators
|
Detail Information
Publications
A study of parenteral iron regimens in hemodialysis patientsA Besarab
Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA
Am J Kidney Dis 34:21-8. 1999..After weekly maintenance 25- to 100-mg iron dextran doses, iron indices can be measured after 1 week; a delay of 2 weeks is not necessary...
An indistinct balance: the safety and efficacy of parenteral iron therapyA Besarab
Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, Michigan 48202, USA
J Am Soc Nephrol 10:2029-43. 1999..Until these answers are known, the importance of carefully crafted iron therapy cannot be overstated...
Iron and cardiac disease in the end-stage renal disease settingA Besarab
Department of Medicine, Henry Ford Hospital, Detroit, MI 48202, USA
Am J Kidney Dis 34:S18-24. 1999..Well-designed prospective studies are needed before the relationship between supplemental iron administration, excess iron, and cardiac disease can be firmly established...
Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patientsA Besarab
Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA
J Am Soc Nephrol 11:530-8. 2000..Reticulocyte hemoglobin content increased only in the study group from 28.5 to 30.1 pg. It is concluded that maintenance of TSAT between 30 and 50% reduces rhEPO requirements significantly over a 6-mo period...
Preventing vascular access dysfunction: which policy to followAnatole Besarab
Division of Nephrology, Department of Medicine, University of West Virginia School of Medicine, Morgantown, WV, USA
Blood Purif 20:26-35. 2002..Strategies and resources needed to achieve these policies are presented. The need for a team approach is emphasized...
Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysisA Gupta
Department of Pharmacy Services, Henry Ford Hospital, Detroit, Michigan, USA
Kidney Int 55:1891-8. 1999..Hemodialysis patients need iron to replenish ongoing losses. We evaluated the short-term safety and efficacy of infusing soluble ferric pyrophosphate by dialysate...
The native arteriovenous fistula in 2007. Research needsA Besarab
Department of Medicine, Henry Ford Health System, Detroit, Michigan, USA
J Nephrol 20:668-73. 2007..Given that the quality of the available literature in nephrology is often suboptimal, nephrologists need to pay special attention to methodology issues before embarking on expensive multicenter studies...
De novo once-monthly darbepoetin alpha treatment for the anemia of chronic kidney disease using a computerized algorithmic approachE Chalhoub
Henry Ford Hospital, Division of Nephrology and Hypertension, Detroit, MI 48202, USA
Clin Nephrol 76:1-8. 2011..We hypothesized that once-monthly (QM) algorithmically dosed darbepoetin ? (DA) and iron administration would successfully treat anemia of CKD in ESA-naïve CKD subjects...
Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patientsA Besarab
West Virginia University School of Medicine, Dialysis Unit, Ruby Memorial Hospital, Morgantown, WV, USA
Nephrol Nurs J 28:429-34. 2001..The implications of these findings for clinical practice are also discussed...
Defining a renal anemia management periodA Besarab
West Virginia University, Department of Medicine, Robert C Byrd Health Science Center, Morgantown, WV 26506, USA
Am J Kidney Dis 36:S13-23. 2000..Treatment of anemia during the RAMP has the potential to ameliorate, or even prevent, significant future morbidity in patients with CRI...
Effects of systemic hemodynamics on flow within vascular accesses used for hemodialysisA Besarab
Department of Medicine, West Virginia University School of Medicine, Henry Ford Hospital, USA
ASAIO J 47:501-6. 2001..Cardiac output, MAP, and the arterial segment resistance influence QA in both access types and need to be considered when evaluating QA as part of the trend analysis for detecting access dysfunction...
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II studyR Provenzano
Division of Nephrology, St John Hospital, 22201 Moross Road, Suite 150, Detroit, MI 48236, USA
Clin Nephrol 67:306-17. 2007..E.R.A.) to correct anemia at extended administration intervals in erythropoiesis-stimulating agent-na?ve patients with chronic kidney disease (CKD) not on dialysis and to determine its optimal starting dose...
The native arteriovenous fistula in 2007. Surveillance and monitoringA Besarab
Department of Medicine, Henry Ford Health System, Detroit, Michigan, USA
J Nephrol 20:656-67. 2007....
Use of aspirin associates with longer primary patency of hemodialysis graftsBradley S Dixon
Division of Nephrology, University of Iowa College of Medicine, E 300D GH, 200 Hawkins Drive, Iowa City, IA 52242 1081, USA
J Am Soc Nephrol 22:773-81. 2011..In conclusion, use of aspirin associates with a trend toward longer primary unassisted patency of newly placed hemodialysis grafts similar to that observed for ERDP/ASA...
Recommended standards for reports dealing with arteriovenous hemodialysis accessesAnton N Sidawy
Committee on Reporting Standards for Arterio-Venous Accesses of The Society for Vascular Surgery and the American Association for Vascular Surgery, Washington, DC, USA
J Vasc Surg 35:603-10. 2002....
Changes noted to KDOQI guidelines for vascular accessAnatole Besarab
Kidney Disease Outcomes Quality Initiative Workgroup for Vascular Access
Nephrol News Issues 20:36. 2006
Access monitoring is worthwhile and valuableAnatole Besarab
Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, MI 48301, USA
Blood Purif 24:77-89. 2006....
Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice GuidelinesHugh C Rayner
Birmingham Heartlands Hospital, United Kingdom
Am J Kidney Dis 44:22-6. 2004..CONCLUSION: The DOPPS will continue to monitor practice trends and explore whether greater application of guidelines will lead to fewer access complications and improved longevity for hemodialysis patients...
Vascular access for hemodialysis: 2004 and beyondAnatole Besarab
Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan, USA
Curr Opin Nephrol Hypertens 13:623-9. 2004....
Vascular access: issues and managementAnatole Besarab
Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Mich, USA
Contrib Nephrol 142:29-46. 2004
Resolved: Fistulas are preferred to grafts as initial vascular access for dialysis. ProAnatole Besarab
Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, MI 48301, USA
J Am Soc Nephrol 19:1629-31. 2008..Here the various positions are examined from multiple perspectives...
Dynamic venous access pressure ratio test for hemodialysis access monitoringStanley Frinak
Department of Medicine, Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
Am J Kidney Dis 40:760-8. 2002..We developed a method to prospectively monitor AVGs that uses an algorithm to calculate venous access pressure (VAP) during HD from the venous drip chamber pressure (VDP)...
Utility of static pressure ratio recording during angioplasty of arteriovenous graft stenosisArif Asif
Division of Nephrology, Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
Semin Dial 19:551-6. 2006..33 +/- 0.02). Qa increased significantly in 74 of 83 (89%) procedures (before = 572 +/- 201, after = 1109 +/- 368 ml/min; p < 0.001). SPR measurements can assist in hemodynamic assessment of an AVG during angioplasty procedure...
More than a decade of experience and still no consensus: controversies in iron therapyAnatole Besarab
Division of Nephrology and Hypertension, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
Clin J Am Soc Nephrol 1:S1-3. 2006
Interventional nephrology: from episodic to coordinated vascular access careArif Asif
Division of Nephrology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
J Nephrol 20:399-405. 2007..Challenges for the future include awareness of this subspecialty and development of training programs at academic centers on a larger scale...
Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targetsSteven Fishbane
Division of Nephrology, Department of Medicine, Winthrop University Hospital, Mineola, New York, USA
Clin J Am Soc Nephrol 2:1274-82. 2007....
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trialMarian Klinger
Department of Nephrology and Transplantation Medicine, Medical University, Wroclaw, Poland
Am J Kidney Dis 50:989-1000. 2007..We examined its efficacy for Hb level correction when administered once every 2 weeks in erythropoiesis-stimulating agent-naive dialysis patients...
The normal hematocrit study--follow-upAnatole Besarab
N Engl J Med 358:433-4. 2008
Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patientsRyan D Kilpatrick
Department of Biostatistics and Epidemiology, Amgen Inc, One Amgen Center Drive, MS 24 2 A, Thousand Oaks, CA 91320, USA
Clin J Am Soc Nephrol 3:1077-83. 2008..Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated...
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal diseaseAnatole Besarab
Division of Nephrology and Hypertension, Department o f Medicine, Henry Ford Hospital, Detroit, Michigan, USA
Clin Ther 29:626-39. 2007..A continuous erythropoietin receptor activator (C.E.R.A.) is currently in development for the treatment of anemia in patients with chronic renal disease (CRD) receiving or not receiving dialysis treatment...
Vascular mapping techniques: advantages and disadvantagesArif Asif
Division of Nephrology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida 3136, USA
J Nephrol 20:299-303. 2007..This article presents advantages and disadvantages of the 3 mapping techniques and proposes a strategy to conduct vascular mapping in patients with chronic kidney disease...
Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patientsAnatole Besarab
Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA
Am J Kidney Dis 40:439-46. 2002..Recommendations of current US and European guidelines, which encourage the use of SC administration, not only have a sound rationale in terms of efficacy and safety, but also have a sound economic basis...
What common practices in dialysis units can be altered to improve patient care?Anatole Besarab
Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan 48201, USA
Semin Dial 17:16-7. 2004
Effect of differing blood lines on delivered blood flow during hemodialysisJunaid Ahmed
Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
Am J Kidney Dis 44:498-508. 2004..14; P = 0.04) with RS than CS tubing sets. CONCLUSION: Differences in [Q P - Q B ] occur both in vitro and in vivo, are much smaller with RS than CS tubing sets, and result in a greater delivered Kt/V of up to 0.14 for RS...
Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemiaNizar Attallah
Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
Am J Kidney Dis 47:644-54. 2006..We conducted an open-label prospective study to assess the effect of vitamin C, an antioxidant, on EPO-hyporesponsive anemia in hemodialysis patients with unexplained hyperferritinemia...
Antimicrobial locks: putting the lock on catheter infectionsCarol Manierski
Department of Nephrology and Hypertension, Henry Ford Health System, Detroit, MI 48202, USA
Adv Chronic Kidney Dis 13:245-58. 2006..The objectives of this review are to evaluate the current body of evidence espousing the utilization of an antimicrobial lock solution in tunneled cuffed and uncuffed catheters that are utilized during chronic intermittent hemodialysis...
How can the cardiac death rate be reduced in dialysis patients?Anatole Besarab
Department of Medicine, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, West Virginia 26506, USA
Semin Dial 15:24-6. 2002
Does full versus partial correction of anemia have additional cardiac benefit in incident hemodialysis patients?Anatole Besarab
Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
Nat Clin Pract Nephrol 1:70-1. 2005
Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremiaUday S Nori
Division of Nephrology, Henry Ford Hospital, Detroit, MI 48202, USA
Am J Kidney Dis 48:596-605. 2006..020. CONCLUSION: Antibiotic lock solutions are superior to the standard heparin lock alone in the prevention of CRBs, and low-dose gentamicin solution has efficacy similar to that of greater concentrations used in previous studies...
Clinical epidemiology of arteriovenous fistula in 2007Pietro Ravani
Clinical Epidemiology Unit, Memorial University of Newfoundland, St John s, Newfoundland, Canada
J Nephrol 20:141-9. 2007..Recent experience from the United States suggests that multidisciplinary management is the most appropriate approach to deal with all the multifaceted aspects of end-stage renal disease care and to increase the likelihood of success...
Biology of arteriovenous fistula failurePrabir Roy-Chaudhury
Division of Nephrology and Hypertension, University of Cincinnati, Cincinnati, Ohio 45267 0585, USA
J Nephrol 20:150-63. 2007..Finally, we will end with a brief description of some state-of-the-art clinical trials that are attempting to apply some of these novel therapeutic concepts to the recalcitrant clinical problem of AV fistula failure...
Autogenous arteriovenous fistula optionsLawrence M Spergel
Dialysis Management Medical Group, San Francisco, California 94109, USA
J Nephrol 20:288-98. 2007..Optimizing autogenous options for hemodialysis requires vessel mapping and a surgeon's willingness to invest additional time and effort...
Surgical salvage of the autogenous arteriovenous fistula (AVF)Lawrence M Spergel
Dialysis Management Medical Group, San Francisco, CA 94109, USA
J Nephrol 20:388-98. 2007..These include strategies to salvage primary failed fistulae due to early thrombotic events or lack of maturation, ischemia, venous hypertensive problems, aneurysms and infections...
